Table 1 Demographic and clinicopathologic characteristics of non-metastatic nasopharyngeal carcinoma patients in the training set, internal validation set, and IMRT cohort
Variable | Primary cohort [cases (%)] | IMRT cohort [cases (%)] | ||
|---|---|---|---|---|
Total | Training set | Validation set | ||
Total | 1520 | 1216 | 304 | 464 |
Sex | ||||
 Male | 1161 (76.4) | 922 (75.8) | 239 (78.6) | 361 (77.8) |
 Female | 359 (23.6) | 294 (24.2) | 65 (21.4) | 103 (22.2) |
Age (years) | ||||
 <50 | 977 (64.3) | 769 (63.2) | 208 (68.4) | 345 (74.4) |
 ≥50 | 543 (35.7) | 447 (36.8) | 96 (31.6) | 119 (25.6) |
Smoking history | ||||
 No | 789 (51.9) | 630 (51.8) | 159 (52.3) | 271 (58.4) |
 Yes | 731 (48.1) | 586 (48.2) | 145 (47.7) | 193 (41.6) |
Alcohol consumption | ||||
 No | 1282 (84.3) | 1030 (84.7) | 252 (82.9) | 387 (83.4) |
 Yes | 238 (15.7) | 186 (15.3) | 52 (17.1) | 77 (16.6) |
BMI (kg/m2) | ||||
 >26 | 210 (13.8) | 174 (14.3) | 36 (11.8) | 150 (32.3) |
 20–26 | 949 (62.4) | 755 (62.1) | 194 (63.8) | 312 (67.2) |
 <20 | 361 (23.8) | 287 (23.6) | 74 (24.3) | 2 (0.4) |
Hemoglobin level (g/L) | ||||
 >150 | 498 (32.8) | 399 (32.8) | 99 (32.6) | 186 (40.1) |
 ≤150 | 1022 (67.2) | 817 (67.2) | 205 (67.4) | 278 (59.9) |
NLR | ||||
 <3.5 | 1129 (74.3) | 906 (74.5) | 223 (73.4) | 384 (82.8) |
 ≥3.5 | 391 (25.7) | 310 (25.5) | 81 (26.6) | 80 (17.2) |
Platelet count (×109/L) | ||||
 <300 | 1251 (82.3) | 1000 (82.2) | 251 (82.6) | 408 (87.9) |
 ≥300 | 269 (17.7) | 216 (17.8) | 53 (17.4) | 56 (12.1) |
LDH level (U/L) | ||||
 <190 | 897 (59.0) | 717 (59.0) | 180 (59.2) | 352 (75.9) |
 190–240 | 399 (26.3) | 315 (25.9) | 84 (27.6) | 80 (17.2) |
 >240 | 224 (14.7) | 184 (15.1) | 40 (13.2) | 32 (6.9) |
ALP level (U/L) | ||||
 <90 | 1227 (80.7) | 978 (80.4) | 249 (81.9) | 401 (86.4) |
 ≥90 | 293 (19.3) | 238 (19.6) | 55 (18.1) | 63 (13.6) |
Histological type | ||||
 WHO I | 6 (0.4) | 5 (0.4) | 1 (0.3) | 1 (0.2) |
 WHO II | 102 (6.7) | 78 (6.4) | 24 (7.9) | 41 (8.8) |
 WHO III | 1412 (92.9) | 1133 (93.2) | 279 (91.8) | 422 (90.9) |
T stage | ||||
 T1 | 262 (17.2) | 198 (16.3) | 64 (21.1) | 86 (18.5) |
 T2 | 746 (49.1) | 603 (49.6) | 143 (47.0) | 119 (25.6) |
 T3 | 267 (17.6) | 213 (17.5) | 54 (17.8) | 191 (41.2) |
 T4 | 245 (16.1) | 202 (16.6) | 43 (14.1) | 68 (14.7) |
N stage | ||||
 N0 | 419 (27.6) | 337 (27.7) | 82 (27.0) | 116 (25.0) |
 N1 | 642 (42.2) | 510 (41.9) | 132 (43.4) | 193 (41.6) |
 N2 | 408 (26.8) | 326 (26.8) | 82 (27.0) | 144 (31.0) |
 N3 | 51 (3.4) | 43 (3.5) | 8 (2.6) | 11 (2.4) |
TNM stage | ||||
 I | 79 (5.2) | 60 (4.9) | 19 (6.3) | 43 (9.3) |
 II | 638 (42.0) | 511 (42.0) | 127 (41.8) | 113 (24.4) |
 III | 515 (33.9) | 408 (33.6) | 107 (35.2) | 231 (49.8) |
 IV | 288 (18.9) | 237 (19.5) | 51 (16.8) | 77 (16.6) |
VCA-IgA titer | ||||
 <1:1280 | 1275 (83.9) | 1013 (83.3) | 262 (86.2) | 420 (90.5) |
 ≥1:1280 | 245 (16.1) | 203 (16.7) | 42 (13.8) | 44 (9.5) |
EA-IgA | ||||
 Negative | 334 (22.0) | 272 (22.4) | 62 (20.4) | 127 (27.4) |
 >0 | 1186 (78.0) | 944 (77.6) | 242 (79.6) | 337 (72.6) |
Anti-DNase (%) | ||||
 ≤50 | 516 (33.9) | 407 (33.5) | 109 (35.9) | 221 (47.6) |
 >50 | 1004 (66.1) | 809 (66.5) | 195 (64.1) | 205 (44.2)a |
Neoadjuvant chemotherapy | ||||
 Yes | 997 (65.6) | 800 (65.8) | 197 (64.8) | 304 (65.5) |
 No | 523 (34.4) | 416 (34.2) | 107 (35.2) | 160 (34.5) |
Concomitant chemotherapy | ||||
 Yes | 1171 (77.0) | 933 (76.7) | 238 (78.3) | 145 (31.3) |
 No | 349 (23.0) | 283 (23.3) | 66 (21.7) | 319 (68.7) |
Adjuvant chemotherapy | ||||
 Yes | 1513 (99.5) | 1210 (99.5) | 303 (99.7) | 445 (95.9) |
 No | 7 (0.5) | 6 (0.5) | 1 (0.3) | 19 (4.1) |
Radiation dose (Gy) | ||||
 ≤75 | 1329 (87.4) | 1059 (87.1) | 270 (88.8) | 240 (51.7) |
 >75 | 191 (12.6) | 157 (12.9) | 34 (11.2) | 224 (48.3) |